Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy - News-Medical.Net


4/3/2022 12:00:00 AM3 years 1 month ago

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, resulted in continued benefits in patient quality of life a…

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle,… [+6890 chars]

full article...